Divi’s Laboratories, ONGC to BPCL: which shares to buy?

Indian stock indices today bounced back to the positive territory after the US President Donald Trump said trade talks with China were "very productive". Since the start of the year, the market has been quite volatile and BSE Sensex oscillated between 35,000 and 40,000. It is difficult to make investment decisions in stock markets when stocks fall and rise too fast. However, information is wealth. Right information can help investors pick out profitable stocks. Here are the reports of brokerages on these five stocks:

Divi’s Laboratories (BUY):
Divi’s Laboratories (Divi’s) posted a softer-than-expected Q1FY20. Topline grew 17 percent year-on-year (YoY) on a tough base, but declined sequentially in what is a seasonally weak quarter, said Edelweiss. Earnings before interest, tax, depreciation and amortisation (EBITDA) margin came in soft around 33 percent, as the low-margin active pharmaceutical ingredients (APIs) made the product mix unfavourable. Management guided for FY20 constant currency revenue growth of 10 percent, and stable EBITDA margin YoY of 38 percent. Besides, the company expects to conclude its Rs 16.9 billion capital expenditure (capex) by the end of FY20, of which it has already capitalised Rs 1.1 billion. 

"Management expects benefits from this capex for capacity expansion to start accruing from FY21. Maintain ‘BUY’ with a target price of Rs 1,830."

ONGC (BUY):
Edelweiss said with the immensely bountiful KG-98/2 coming on stream and eligible for deepwater pricing, gas revenue would surge, which will be a key driver of earnings growth. Valuations continue to trend lower despite the overhang of LPG subsidy sharing abating. "We estimate a 9% EPS CAGR over FY19–21 while valuations remain undemanding at 4.4x FY21E PE. Maintain ‘BUY/SO’ with a revised TP at Rs 197/share."

Bharat Petroleum Corporation (BUY):
HDFC Securities said that inventory losses and shutdown of Bharat Petroleum Corporation (BPCL)’s refinery has resulted in a muted 1Q performance. "However, we maintain our BUY owing to its impeccable refining assets and healthy free cash flows (Rs 66.55bn) over FY21-22E."

Dr. Lal Pathlabs (BUY):
The stock trades at 34.8x FY20E and 28.2x FY21E EPS. "We maintain ‘BUY/SP’ with TP of INR1,240 on December 2020E EPS. Our valuation uses PE methodology as DLPL’s business: i) is a low-capex, high-RoCE model, closer to domestic pharma and FMCG; and ii) has a strong brand equity in an underpenetrated domestic market with high growth momentum. Key risk to our call is regulatory intervention via pricing control," an Edelweiss report said.

Whirlpool (BUY):
We expect Whirlpool of India (WHIRL)’s market share to improve with stock keeping unit (SKU) ramp up, aggressive marketing and distribution expansion, while maintaining tight leash on costs, Edelweiss said. "Hence, we estimate it to post 24% earnings CAGR and strong 60 percent free cash-to-PAT conversion over FY19–21. We maintain ‘BUY/SO’ with a target price of Rs 1,755. The stock is trading at 38x/31x FY20/21E EPS."